Background: In recent years, the changes of cognitive function in mild cognitive impairment have attracted attention. Methods/design: We will follow up at 3. The primary outcome will be the measurement of cognitive function using neuropsychological assessment scales such as MOCA, MMSE, etc... Minor variables will be included plasma biomarkers (Aβ, Tau, GFAP, etc.), multimodal brain electrophysiology (P300, VP300, heart rate variability, etc.), and neuroimaging indicators (NODDI).
Study Type
OBSERVATIONAL
Enrollment
200
observational study
Fujian Medical University Union Hospital
Fuzhou, Fujian, China
RECRUITINGChanges in Montreal Cognitive Assessment (MoCA) scores after 3 months.
The MOCA scale scores range from 0 to 30, with higher scores indicating better cognition
Time frame: Participants will be followed up for 3 months after baseline.
Changes in Plasma amyloid protein levels after 3 months.
Plasma amyloid protein(ug/ml) is an important indicator of cognitive function.
Time frame: Participants will be followed up for 3 months after baseline.
Changes in Plasma tau levels after 3 months.
Plasma tau(ug/ml) is an important indicator of cognitive function
Time frame: Participants will be followed up for 3 months after baseline.
Changes in Blood pressure (mmHg) after 3 months.
An experienced physician will measure blood pressure on the right upper arm after the subject rest for 5 min, taking the average of the two measurements as the final result.
Time frame: Participants will be followed up for 3 months after baseline.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.